×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
URGN – urogen pharma ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
URGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/9
09:50 am
urgn
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target [Yahoo! Finance]
Medium
Report
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target [Yahoo! Finance]
11/7
02:31 am
urgn
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
11/6
11:24 am
urgn
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/6
08:00 am
urgn
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
Medium
Report
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
11/5
08:00 am
urgn
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
Low
Report
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
10/30
08:00 am
urgn
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
Medium
Report
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
10/28
08:00 am
urgn
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
Medium
Report
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
10/19
11:01 am
urgn
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years [Yahoo! Finance]
Medium
Report
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
08:00 am
urgn
urogen pharma ltd. - ordinary shares
BEAT
Report
-1.6%
urogen pharma ltd. - ordinary shares
8/13/2024
08:00 am
urgn
urogen pharma ltd. - ordinary shares
MISS
Report
3.1%
urogen pharma ltd. - ordinary shares
5/13/2024
08:00 am
urgn
urogen pharma ltd. - ordinary shares
MISS
Report
2.6%
urogen pharma ltd. - ordinary shares
3/14/2024
08:00 am
urgn
urogen pharma ltd. - ordinary shares
MISS
Report
-18.0%
urogen pharma ltd. - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
06:16 am
urgn
Form SC 13D/A UroGen Pharma Ltd. Filed by: Pontifax Management III G.P. (2011) Ltd.
Low
Report
Form SC 13D/A UroGen Pharma Ltd. Filed by: Pontifax Management III G.P. (2011) Ltd.
11/14
07:46 pm
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: Point72 Asset Management, L.P.
11/14
05:47 pm
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Medium
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
11/14
04:47 pm
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: GREAT POINT PARTNERS LLC
Medium
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: GREAT POINT PARTNERS LLC
11/14
12:05 pm
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: MENORA MIVTACHIM HOLDINGS LTD.
Low
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: MENORA MIVTACHIM HOLDINGS LTD.
11/14
08:37 am
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: COWEN AND COMPANY, LLC
Neutral
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: COWEN AND COMPANY, LLC
11/14
06:45 am
urgn
Form SC 13G/A UroGen Pharma Ltd. Filed by: RTW INVESTMENTS, LP
Neutral
Report
Form SC 13G/A UroGen Pharma Ltd. Filed by: RTW INVESTMENTS, LP
11/12
09:35 am
urgn
Form SC 13G UroGen Pharma Ltd. Filed by: Adage Capital Management, L.P.
Low
Report
Form SC 13G UroGen Pharma Ltd. Filed by: Adage Capital Management, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 8-K UroGen Pharma Ltd. For: Mar 20
18.6%
11/12 Q3/2019 9/30/2019 EPS -1.060 ZacksConsensus -1.260 ActVsEst 0.200 - Beat 13.6%
4/13 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. 11.3%
4/17 Urogen Pharma Ltd (NASDAQ: URGN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $45.00 to $47.00. They now have an "outperform" rating on the stock. 9.9%
4/16 UruGen shares jump 10% on FDA approval of rare cancer treatment [MarketWatch] 9.6%
4/3 UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer 8.1%
11/18 Form 4 UroGen Pharma Ltd. For: Nov 14 Filed by: Mullennix Stephen 8.0%
12/6 UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 6.7%
2/14 Form SC 13G/A UroGen Pharma Ltd. Filed by: Wildcat Capital Management, LLC 6.6%
1/16 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. 6.5%
11/12 Q3/2019 9/30/2019 EPS -1.060 ZacksConsensus -1.260 ActVsEst 0.200 - Beat 13.6%
4/13 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. 11.3%
4/17 Urogen Pharma Ltd (NASDAQ: URGN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $45.00 to $47.00. They now have an "outperform" rating on the stock. 9.9%
4/16 UruGen shares jump 10% on FDA approval of rare cancer treatment [MarketWatch] 9.6%
4/3 UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer 8.1%
11/18 Form 4 UroGen Pharma Ltd. For: Nov 14 Filed by: Mullennix Stephen 8.0%
12/6 UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 6.7%
2/14 Form SC 13G/A UroGen Pharma Ltd. Filed by: Wildcat Capital Management, LLC 6.6%
1/16 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. 6.5%
TOP News Decliners
9/24
Form 8-K UroGen Pharma Ltd. For: Sep 24
-19.9%
4/30 The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial -12.2%
4/16 Form 8-K UroGen Pharma Ltd. For: Apr 15 -7.8%
2/12 Form SC 13D/A UroGen Pharma Ltd. Filed by: Arkin Moshe -5.3%
11/12 UroGen Pharma Ltd. (URGN) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.9%
8/5 UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 -4.7%
5/11 UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.6%
5/28 Form 8-K UroGen Pharma Ltd. For: May 21 -4.5%
9/26 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. -4.4%
5/9 UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript [The Motley Fool] -3.1%
4/30 The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial -12.2%
4/16 Form 8-K UroGen Pharma Ltd. For: Apr 15 -7.8%
2/12 Form SC 13D/A UroGen Pharma Ltd. Filed by: Arkin Moshe -5.3%
11/12 UroGen Pharma Ltd. (URGN) Q3 2019 Earnings Call Transcript [The Motley Fool] -4.9%
8/5 UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 -4.7%
5/11 UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.6%
5/28 Form 8-K UroGen Pharma Ltd. For: May 21 -4.5%
9/26 Urogen Pharma Ltd (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at Cowen Inc. -4.4%
5/9 UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript [The Motley Fool] -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: